Clearmind submits FDA recommendations on psychedelic therapies

Clearmind Medicine (NASDAQ:CMND) submitted FDA recommendations on psychedelic therapies, focusing on non-hallucinogenic treatments and patient access. The company cited ongoing clinical trials and called for collaborations with U.S. federal agencies. Clearmind develops psychedelic-derived compounds for various disorders and holds 32 granted patents.

Original reporting
Published Oct 7, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$CMND
Neutral
medium confidence
Mentioned
$CMND
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CMNDNeutralMed
01

Why it matters

The FDA recommendation filing is the first public disclosure of this regulatory step, offering a fresh data point for traders.

02

Market read

Regulatory engagement could be a catalyst for CMND's stock, but the actual impact hinges on future FDA decisions.

03

What to watch

Potential competition from other psychedelic biotech firms and the uncertain path to Breakthrough Designation.

Relevance 6/10Novelty 7/10Timing: today

Background

Clearmind Medicine (NASDAQ:CMND) is a clinical‑stage biotech developing non‑hallucinogenic psychedelic compounds for neuropsychiatric and addiction disorders.

Company-level read

Ticker impact

$CMNDNeutralMedium confidence
Context

Clearmind Medicine filed FDA recommendations on psychedelic therapies, a new regulatory engagement that could affect its approval timeline and market perception.

Expected impact

potential upside as market prices in possible regulatory progress

Evidence & confidence

First disclosure of an FDA submission; micro‑cap biotech where regulatory news drives price, but impact depends on FDA response.

Market effects

May signal growing interest in non‑hallucinogenic psychedelic therapeutics, influencing other biotech peers.

Limited to U.S. biotech sector; no broader regional effect.

Low; primarily relevant to investors tracking FDA‑regulated biotech developments.

Counterpoint

Regulatory submissions often do not translate into near‑term price moves; investors may wait for concrete FDA feedback.

Key entities

  • Clearmind Medicine Inc.

    Biopharma developing psychedelic‑derived therapies.

  • U.S. Food and Drug Administration

    Agency reviewing the company's recommendations.

Related articles

$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.